E

Exelixis
D

EXEL

35.620
USD
0.79
(2.27%)
Market Closed
Volume
75,834
EPS
1
Div Yield
-
P/E
23
Market Cap
10,172,324,692
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    A
    ARRY
    -0.79000
    (-10.35%)
    6.84500 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    More
News

Title: Exelixis

Sector: Healthcare
Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.